Effect of cimetidine and pirenzepine in combination on 24 hour intragastric acidity in subjects with previous duodenal ulceration

J G WILLIAMS, M DEAKIN, AND J K RAMAGE

From the Department of Gastroenterology, RN Hospital Haslar, Gosport, Hampshire

SUMMARY  Intragastric pH was monitored during 24 hours in eight volunteers with duodenal ulcer disease in remission, while on placebo, cimetidine 400 mg bd, pirenzepine 50 mg bd, cimetidine 400 mg bd + pirenzepine 50 mg bd, cimetidine 200 mg bd + pirenzepine 25 mg bd. The control of intragastric acidity during the 24 hour period by the combination of low dose cimetidine and pirenzepine was significantly better than with cimetidine, or pirenzepine alone in full dosage. This difference was most apparent after breakfast but was still present after lunch when cimetidine had no significant effect. Combination treatment is a logical approach when continuous control of intragastric acidity is needed, but a three times daily regimen will be necessary to cover the 24 hours.

Pirenzepine is known to inhibit gastric acid secretion induced by a variety of stimuli, including pentagastrin,

Insulin,

Sham-feeding,

and a peptone meal.

Pirenzepine is thought to inhibit selectively the type I muscarinic receptor located in vagal ganglia.

Cimetidine, however, inhibits gastric acid secretion by antagonism of parietal cell H2 receptors.

Combined administration of the two drugs might therefore be expected to result in a greater degree of acid inhibition than with either alone. Londenong et al.

24 demonstrated this effect after intravenous administration of the drugs using in vivo titration and a peptone meal stimulus. As the therapeutic effect of cimetidine and pirenzepine in combination is being assessed in the treatment of duodenal ulcer in clinical trial we considered it important to evaluate the effects on intragastric acidity throughout a 24 hour period using conventional oral dosages.

Methods

Subjects

Eight male volunteers (age range 28–42 years) were studied. Each had a history of duodenal ulcer diagnosed by endoscopy but was symptomatically in remission. The length of history of duodenal ulcer was between 18 months and 11 years. None of the volunteers had coexisting medical illness, or was taking medication.

Each volunteer was studied on five separate occasions at least one week apart. Each study day started at 0730 hours, after an overnight fast, and lasted for 24 hours. Between 0730 and 0745 hours a 10F gauge Salem sump nasogastric tube was passed and the position checked by water recovery.

Standard meals comprising 375 ml Clinifeed 500 together with one Oxo cube dissolved in 200 ml hot water were taken by mouth at 0800, 1300, and 1800 hours. The timing of additional tea and cigarettes was kept constant for each individual on all study days.

Five millilitre samples of gastric juice were aspirated for pH measurement (pHm 82, Radiometer, Copenhagen) at 15 minute intervals after meals for two hours, half hourly between meals, and hourly overnight. Aspirates taken within one hour of ingestion of the tablets were returned to the stomach to avoid aspiration of active drugs.

The treatment periods were randomised, and the study conducted in a double blind fashion using a double dummy tablet technique. Tablets were given at 2300 hours on the night before each study and at 0800 and 2300 hours on the study days.

Blood samples were taken before and after each study period for full blood count, plasma urea and
Effect of cimetidine and pirenzepine in subjects with previous duodenal ulceration

Fig. 1 Mean hourly 24 hour hydrogen ion activity for each treatment group. (P50 = pirenzepine 50 mg bd, C400 = cimetidine 400 mg bd, C400 P50 = cimetidine 400 mg + pirenzepine 50 mg bd; C200 P25 = cimetidine 200 mg + pirenzepine 25 mg bd; mean ± SEM, n = 8).

electrolytes, and serum bilirubin, aspartate transaminase, gamma glutamyl transferase, and alkaline phosphatase.

For analysis of the data pH values were converted to hydrogen ion activity, and mean 24 hour values (mean of hourly readings) for each subject were compared between treatment groups. Area under the hydrogen ion activity curve was used to compare the effect of the different treatments during the four hours after meals. The Wilcoxon’s rank sum test was used to test for significance, comparing by rank the data for each subject on different treatments. For descriptive purposes only the data have been displayed graphically as mean values with standard errors of the mean (SEM).

Results

Mean hourly hydrogen ion activity (mmol/l) for each treatment group over the 24 hour period has been displayed in Figure 1.

Pirenzepine alone had no significant effect on intragastric acidity and did not change the 24 hour H⁺ activity as compared with placebo (Fig. 2). Cimetidine alone was significantly better than placebo or pirenzepine, resulting in a 26% decrease in mean hourly hydrogen ion activity (p < 0.05). Both high and low dose combinations produced a further lowering of intragastric acidity. The effects of both combinations were similar with the low dose combination being significantly better than either pirenzepine or cimetidine alone in twice the dosage (p < 0.05). The hydrogen ion activity profile for this dose has been included in Figure 2. The effect of the

Fig. 2 Mean 24 hour hydrogen ion activity profile for placebo (● — ●), pirenzepine 50 mg bd (○—○—○) and pirenzepine 25 mg + cimetidine 200 mg bd (□—□—□) (n = 8).
Fig. 3  Area under the hydrogen ion activity curve after breakfast (0800 to 1200 h) and lunch (1300 to 1700 h) for each treatment group. (mean±SEM, n=8).

Fig. 4  Hourly nocturnal (2400-0800 h) hydrogen ion activity for each treatment group. (mean±SEM, n=8).

Discussion

In this study we have shown that to lower intragastric acidity in subjects with previous duodenal...
The method we use gives a standard reproducible meal three times a day and this technique allows comparison of effects between meals (and between other treatments in identical studies). The meal is a potent stimulus to acid secretion, requiring about 40 mmol/h of sodium bicarbonate to maintain a constant pH of 5.5 in vivo titration studies in normal subjects.7

The best method of expression of data related to intragastric acidity is controversial.8 We have chosen to present the data in this study as hydrogen ion activity, although analysis of unconverted pH data yields the same statistical conclusions. For statistical evaluation we have used a non-parametric method of analysis as hydrogen ion activity is not normally distributed, although a paired Student’s t test yields unchanged conclusions.

Anticholinergic drugs given orally in acceptable doses have rarely been shown to lower intragastric acidity.9 Pirenzepine is no exception to this10 which is confirmed by our data. We have also confirmed the significant effect of cimetidine given alone,11 and shown that the two drugs given in combination produce a further decrease in hydrogen ion activity that is greater than can be expected by an additive effect, particularly as this is seen when the combination doses are halved. This synergism is most apparent after a meal stimulus and is even seen five to nine hours after drug administration, when cimetidine alone has no effect.

At night little additional benefit is seen for either combination over cimetidine alone. This is not surprising in this group of duodenal ulcer subjects who respond well to cimetidine, in contrast with a group of non-responders whose nocturnal acid output was little decreased by cimetidine alone, but showed a significant lowering on cimetidine 1 g daily (200 mg tds, 400 mg nocte) combined with atropine 4-8 mg daily (1-2 mg qds with food).12 A previous study13 had shown that the addition of atropine 2-4 mg/day to cimetidine 1 g/day failed to reduce further 24 hour intragastric acidity in duodenal ulcer patients who had responded to cimetidine. This dose produced no side effects but the higher dose caused anticholinergic symptoms in all seven subjects studied, in contrast with our experience with pirenzepine where no side effects were encountered. This is in keeping with the gastro-selective (M1) anticholinergic properties of pirenzepine.14

The use of the two drugs in combination is logical in clinical situations where profound inhibition of intragastric acidity is required.15-19 Our data suggest, however, that if continuous inhibition is needed from oral treatment, a three times daily dosing schedule should be used. Intravenous ranitidine and pirenzepine in combination have been shown to produce a more profound inhibition of peptone stimulated secretion than cimetidine and pirenzepine20 but the duration of this effect has not yet been reported.

References
12 Gledhill T, Buck M, Hunt RH. Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders. Gut 1984; 25: 1211-6.


Effect of cimetidine and pirenzepine in combination on 24 hour intragastric acidity in subjects with previous duodenal ulceration.

J G Williams, M Deakin and J K Ramage

*Gut* 1986 27: 428-432
doi: 10.1136/gut.27.4.428

Updated information and services can be found at:
http://gut.bmj.com/content/27/4/428

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/